Non-Small Cell Lung Cancer
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
The approval is for certain patients with advanced, unresectable, or metastatic NSCLC with an NRG1 gene fusion.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.